Scores by echosens
Enhance FibroScan® liver disease assessment with biological markers
Identification of at-risk MASH* patients
*Formerly known as NASH
Current MASH drug developments focus on patients with MASH at-risk of progression to cirrhosis or with compensated cirrhosis defined by Active Fibrotic MASH (MASH + NAS≥4 + F≥2).
Fast™ combines FibroScan® examination results (LSM by VCTE™ & CAP™) with an easily accessible blood biomarker (AST) to help identify patients with active fibrotic-MASH, at the point-of-care, reducing invasive and costly procedures.
Good to excellent performance in derivation cohort as well as in external validation cohorts from different clinical settings (MASLD tertiary care unit, screening, bariatric surgery) and geographical origins (USA, Europe, Asia). Several publications advocate the use of Fast™.
Fast™ calculator is a tool for clinicians, computed from LSM and CAP (obtained from FibroScan® device) and AST blood parameter measurement, to aid in the identification of a patient with suspicion of MASLD as being at risk for active fibrotic MASH (MASH+NAS≥4+F≥2).
Enhance FibroScan® liver disease assessment with biological markers
The non-invasive solution for comprehensive management of liver health
Your everyday FibroScan® companion – free application
Optimize clinical workflows with real-time secure data transmission